-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Using Disease Modifying Therapies in Sickle Cell Disease

Program: Education Program
Session: Improving Outcomes for Individuals With Sickle Cell Disease: Are We Moving the Needle?
Hematology Disease Topics & Pathways:
clinical trials, epidemiology, Clinical Research, drug development
Monday, December 11, 2023, 4:30 PM-5:45 PM

Kenneth I. Ataga, MD

Center for Sickle Cell Disease, University of Tennessee Health Sciences Center, Memphis, TN

Disclosures: Ataga: Roche: Consultancy, Honoraria; Novo Nordisk: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; Vertex: Other: Data Monitoring Committee; Fulcrum Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Hillhurst Biopharmaceuticals: Membership on an entity's Board of Directors or advisory committees; NHLBI: Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees; Takeda Pharmaceuticals: Research Funding; Biomarin: Consultancy, Honoraria; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; FDA: Research Funding.

See more of: Improving Outcomes for Individuals With Sickle Cell Disease: Are We Moving the Needle?
See more of: Education Program
Previous Presentation | Next Presentation >>